Liver regeneration and its impact on post-hepatectomy metastatic tumour recurrence

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2161-2170

  Paschos, Konstantinos A ^a   Bird, Nigel C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Colorectal cancer; Cytokine; Growth factor; Hepatectomy; Liver metastasis; Liver regeneration; Review; Tumour recurrence

Indexed keywords

BEVACIZUMAB; CANCER GROWTH FACTOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GELATINASE B; HLA ANTIGEN CLASS 1; HYALURONIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NORADRENALIN; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; SUNITINIB; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN;

CELL INTERACTION; COLORECTAL CANCER; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; HEPATOBLASTOMA; HUMAN; KUPFFER CELL; LIVER CELL; LIVER METASTASIS; LIVER PARENCHYMA; LIVER REGENERATION; LIVER RESECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

HEPATECTOMY; HEPATOCYTE GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; NEOPLASM RECURRENCE, LOCAL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955069295     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Yamane B and Weber S: Liver-directed treatment modalities for primary and secondary hepatic tumors. Surg Clin North America 89(1): 97-113, 2009.
2. Koshariya M, Jagad RB, Kawamoto J, Papastratis P, Kefalourous H, Porfiris T, Tzouma C and Lygidakis NJ: An update and our experience with metastatic liver disease. Hepatogastroenterol 54(80): 2232-2239, 2007.
3. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, GA ES, Francisci S, Santaquilani M, Verdecchia A, Storm HH and Young JL: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancer Oncol 9(8): 730-756, 2008.
4. Nanashima A, Araki M, Tobinaga S, Kunizaki M, Hidaka S, Shibata K, Mochinaga K, Sawai T, Isomoto H, Ohnita K, Uehara M and Nagayasu T: Relationship between period of survival and clinicopathological characteristics in patients with colorectal liver metastasis. Eur J Surg Oncol 35(5): 504-509, 2009.
5. Sarpel U, Bonavia AS, Grucela A, Roayaie S, Schwartz ME and Labow DM: Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol 16(2): 379-384, 2009.
6. Xu J, Wei Y, Zhong Y, Fan J, Zhou J, Qin L, Ren L and Qin X: Hepatectomy for liver metastasis of colorectal cancer. Int J Colorec Dis 24(4): 419-425, 2009.
7. Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK and Dematteo RP: Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 13(3): 353-362, 2006. (Pubitemid 43255919)
8. Harun N, Nikfarjam M, Muralidharan V and Christophi C: Liver regeneration stimulates tumor metastases. J Surg Res 138(2): 284-290, 2007. (Pubitemid 46365721)
9. Monte MJ, Marin JJ, Antelo A and Vazquez-Tato J: Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol 15(7): 804-816, 2009.
10. Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK and Kim BI: Abnormal glucose tolerance in young male patients with nonalcoholic fatty liver disease. Liver Int 29(4): 525-529, 2009.
11. Vaquero J and Butterworth RF: Mechanisms of brain edema in acute liver failure and impact of novel therapeutic interventions. Neurological Res 29(7): 683-690, 2007.
12. Clavien PA: Liver regeneration: a spotlight on the novel role of platelets and serotonin. Swiss Med Wkly 138(25-26): 361-370, 2008.
13. Michalopoulos GK: Liver regeneration. J Cell Phys 213(2): 286-300, 2007.
14. Dong Z, Wei H, Sun R and Tian Z: The Roles of Innate Immune Cells in Liver Injury and Regeneration. Cell Mol Immunol 4(4): 241-252, 2007.
15. Mitchell C and Willenbring H: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nature Protocols 3(7): 1167-1170, 2008.
16. Yoneyama H, Kai Y, Koyama J, Suzuki K, Kawachi H, Narumi S and Ichida T: Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury. Medical Mole Morphol 40(4): 191-197, 2007.
17. Cantz T, Manns MP and Ott M: Stem cells in liver regeneration and therapy. Cell Tissue Res 331(1): 271-282, 2008. (Pubitemid 350265492)
18. Fausto N and Campbell JS: The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 120(1): 117-130, 2003.
19. Rutherford A and Chung RT: Acute liver failure: mechanisms of hepatocyte injury and regeneration. Sem Liver Dis 28(2): 167-174, 2008.
20. Marubashi S, Sakon M, Nagano H, Gotoh K, Hashimoto K, Kubota M, Kobayashi S, Yamamoto S, Miyamoto A, Dono K, Nakamori S, Umeshita K and Monden M: Effect of portal hemodynamics on liver regeneration studied in a novel portohepatic shunt rat model. Surgery 136(5): 1028-1037, 2004.
21. Khan Z, Michalopoulos GK and Stolz DB: Peroxisomal localization of hypoxia-inducible factors and hypoxia-inducible factor regulatory hydroxylases in primary rat hepatocytes exposed to hypoxia-reoxygenation. Am J Pathol 169(4): 1251-1269, 2006.
22. Taub R: Liver regeneration 4: transcriptional control of liver regeneration. FASEB J 10(4): 413-427, 1996.
23. Taub R: Liver regeneration: from myth to mechanism. Nature Rev 5(10): 836-847, 2004.
24. Pediaditakis P, Lopez-Talavera JC, Petersen B, Monga SP and Michalopoulos GK: The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat. Hepatology (Baltimore, MD) 34(4 Pt 1): 688-693, 2001.
25. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA and Thorgeirsson SS: Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 101(13): 4477-4482, 2004. (Pubitemid 38437436)
26. Nishino M, Iimuro Y, Ueki T, Hirano T and Fujimoto J: Hepatocyte growth factor improves survival after partial hepatectomy in cirrhotic rats suppressing apoptosis of hepatocytes. Surgery 144(3): 374-384, 2008.
27. Seki E, Kondo Y, Iimuro Y, Naka T, Son G, Kishimoto T, Fujimoto J, Tsutsui H and Nakanishi K: Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings. J Hepatol 48(2): 237-245, 2008.
28. Natarajan A, Wagner B and Sibilia M: The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA 104(43): 17081-17086, 2007.
29. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V and Lau LF: Cytotoxicity of TNFalpha is regulated by integrin-mediated matrix signaling. EMBO J 26(5): 1257-1267, 2007.
30. Haruyama T, Ajioka I, Akaike T and Watanabe Y: Regulation and significance of hepatocyte-derived matrix metalloproteinases in liver remodeling. Bioche Biophys Res Comm 272(3): 681-686, 2000.
31. Argast GM, Campbell JS, Brooling JT and Fausto N: Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication. J Biol Chem 279(33): 34530-34536, 2004.
32. Shimizu T, Togo S, Kumamoto T, Makino H, Morita T, Tanaka K, Kubota T, Ichikawa Y, Nagasima Y, Okazaki Y, Hayashizaki Y and Shimada H: Gene expression during liver regeneration after partial hepatectomy in mice lacking type 1 tumor necrosis factor receptor. J Surg Res 152(2): 178-188, 2009.
33. Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA and Puder M: A critical role for matrix metalloproteinases in liver regeneration. J Surg Res 145(2): 192-198, 2008.
34. Olle EW, Ren X, McClintock SD, Warner RL, Deogracias MP, Johnson KJ and Colletti LM: Matrix metalloproteinase-9 is an important factor in hepatic regeneration after partial hepatectomy in mice. Hepatology (Baltimore, MD) 44(3): 540-549, 2006. (Pubitemid 44433710)
35. Mangnall D, Smith K, Bird NC and Majeed AW: Early increases in plasminogen activator activity following partial hepatectomy in humans. Comp Hepatol 3(1): 11, 2004.
36. Shanmukhappa K, Sabla GE, Degen JL and Bezerra JA: Urokinase-type plasminogen activator supports liver repair independent of its cellular receptor. BMC Gastroenterol 6: 40, 2006.
37. Myronovych A, Murata S, Chiba M, Matsuo R, Ikeda O, Watanabe M, Hisakura K, Nakano Y, Kohno K, Kawasaki T, Hashimoto I, Shibasaki Y, Yasue H and Ohkohchi N: Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 49(3): 363-372, 2008.
38. Nocito A, Georgiev P, Dahm F, Jochum W, Bader M, Graf R and Clavien PA: Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. Hepatology (Baltimore, MD) 45(2): 369-376, 2007.
39. Papadimas GK, Tzirogiannis KN, Panoutsopoulos GI, Demonakou MD, Skaltsas SD, Hereti RI, Papadopoulou-Daifoti Z and Mykoniatis MG: Effect of serotonin receptor 2 blockage on liver regeneration after partial hepatectomy in the rat liver. Liver Int 26(3): 352-361, 2006.
40. Romero-Gallo J, Sozmen EG, Chytil A, Russell WE, Whitehead R, Parks WT, Holdren MS, Her MF, Gautam S, Magnuson M, Moses HL and Grady WM: Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene 24(18): 3028-3041, 2005.
41. Zimmermann A: Regulation of liver regeneration. Nephrol Dial Transplant 19(Suppl 4): iv6-10, 2004.
42. LaMarre J, Hayes MA, Wollenberg GK, Hussaini I, Hall SW and Gonias SL: An alpha 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor-beta 1 in mice. J Chin Inveset 87(1): 39-44, 1991.
43. Nguyen LN, Furuya MH, Wolfraim LA, Nguyen AP, Holdren MS, Campbell JS, Knight B, Yeoh GC, Fausto N and Parks WT: Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. Hepatology (Baltimore, MD) 45(1): 31-41, 2007. (Pubitemid 46144362)
44. Deneme MA, Ok E, Akcan A, Akyildiz H, Soyuer I and Muhtaroglu S: Single dose of anti-transforming growth factor-beta1 monoclonal antibody enhances liver regeneration after partial hepatectomy in biliary-obstructed rats. J Surg Res 136(2): 280-287, 2006.
45. Michalopoulos GK and DeFrances MC: Liver regeneration. Science 276(5309): 60-66, 1997.
46. Wagenaar GT, Chamuleau RA, Pool CW, de Haan JG, Maas MA, Korfage HA and Lamers WH: Distribution and activity of glutamine synthase and carbamoylphosphate synthase upon enlargement of the liver lobule by repeated partial hepatectomies. J Hepatol 17(3): 397-407, 1993.
47. Umeda Y, Iwagaki H, Ozaki M, Ogino T, Iwamoto T, Yoshida R, Shinoura S, Matsuda H, Sadamori H, Tanaka N and Yagi T: Refractory response to growth factors impairs liver regeneration after hepatectomy in patients with viral hepatitis. Hepatogastroenterol 56(93): 971-977, 2009.
48. Gomez D, Morris-Stiff G, Wyatt J, Toogood GJ, Lodge JP and Prasad KR: Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol 98(5): 371-376, 2008.
49. Xiaobin F, Zipei L, Shuguo Z, Jiahong D and Xiaowu L: The Pringle manoeuvre should be avoided in hepatectomy for cancer patients due to its side effects on tumor recurrence and worse prognosis. Med Hypoth 72(4): 398-401, 2009.
50. Pamecha V, Nedjat-Shokouhi B, Gurusamy K, Glantzounis GK, Sharma D and Davidson BR: Prospective evaluation of two-stage hepatectomy combined with selective portal vein embolisation and systemic chemotherapy for patients with unresectable bilobar colorectal liver metastases. Dig Surg 25(5): 387-393, 2008.
51. van Gulik TM, van den Esschert JW, de Graaf W, van Lienden KP, Busch OR, Heger M, van Delden OM, Lameris JS and Gouma DJ: Controversies in the use of portal vein embolization. Dig Surg 25(6): 436-444, 2008.
52. Christophi C, Harun N and Fifis T: Liver regeneration and tumor stimulation - a review of cytokine and angiogenic factors. J Gastrointest Surg 12(5): 966-980, 2008.
53. Elias D, De Baere T, Roche A, Mducreux, Leclere J and Lasser P: During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 86(6): 784-788, 1999. (Pubitemid 29271944)
54. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Matsubara T, Takahashi T, Nakajima T and Muto T: Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 181(2): 153-159, 2001.
55. DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH and Fong Y: Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 4(2): 178-184, 2000.
56. Liu H and Zhu S: Present status and future perspectives of preoperative portal vein embolization. Am J Surg 197(5): 686-690, 2009.
57. Pamecha V, Levene A, Grillo F, Woodward N, Dhillon A and Davidson BR: Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 100(4): 617-622, 2009.
58. Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T and Roche A: Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterol 51(60): 1788-1791, 2004.
59. Meredith K, Haemmerich D, Qi C and Mahvi D: Hepatic resection but not radiofrequency ablation results in tumor growth and increased growth factor expression. Ann Surg 245(5): 771-776, 2007. (Pubitemid 46684107)
60. Mueller L, Hillert C, Moller L, Krupski-Berdien G, Rogiers X and Broering DC: Major hepatectomy for colorectal metastases: is preoperative portal occlusion an oncological risk factor? Ann Surg Oncol 15(7): 1908-1917, 2008.
61. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Ohta K, Yamaguchi T, Matsubara T, Takahashi T, Nakajima T, Muto T, Ikari T, Yanagisawa A and Kato Y: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology (Baltimore, MD) 34(2): 267-272, 2001.
62. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN and Abdalla EK: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94(3): 274-286, 2007.
63. Mentha G, Terraz S, Morel P, Andres A, Giostra E, Roth A, Rubbia-Brandt L and Majno P: Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 96(1): 95-103, 2009.
64. von Schweinitz D, Faundez A, Teichmann B, Birnbaum T, Koch A, Hecker H, Gluer S, Fuchs J and Pietsch T: Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer 85(2): 151-159, 2000.
65. de Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, Marquet RL, Slooff MJ and Terpstra OT: The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology (Baltimore, MD) 22(4 Pt 1): 1263-1272, 1995.
66. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT and Fan ST: Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases - activation of cell invasion and migration pathways. Liver Transpl 13(12): 1669-1677, 2007.
67. Bai L, Mao GP and Cao CP: Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation. J Dig Dis 8(3): 154-159, 2007.
68. Mueller L, Goettsche J, Abdulgawad A, Vashist YK, Meyer J, Wilms C, Hillert C, Rogiers X and Broering DC: Tumor growth-promoting cellular host response during liver atrophy after portal occlusion. Liver Int 25(5): 994-1001, 2005.
69. Koch M, Kienle P, Sauer P, Willeke F, Buhl K, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M and Weitz J: Hematogenous tumor cell dissemination during colonoscopy for colorectal cancer. Surgical Endo 18(4): 587-591, 2004.
70. Yamaguchi K, Takagi Y, Aoki S, Futamura M and Saji S: Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 232(1): 58-65, 2000.
71. Wang JY, Wu CH, Lu CY, Hsieh JS, Wu DC, Huang SY and Lin SR: Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg 30(6): 1007-1013, 2006. (Pubitemid 43824411)
72. Guller U, Zajac P, Schnider A, Bosch B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M and Marti WR: Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 236(6): 768-775; discussion 775-766, 2002.
73. Liotta LA, Kleinerman J and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 34(5): 997-1004, 1974.
74. Butler TP and Gullino PM: Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 35(3): 512-516, 1975.
75. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK and Munn LL: Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97(26): 14608-14613, 2000.
76. Yokoyama N, Shirai Y, Ajioka Y, Nagakura S, Suda T and Hatakeyama K: Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases. Cancer 94(6): 1642-1647, 2002.
77. Ikawa K, Terashima Y, Sasaki K and Tashiro S: Genetic detection of liver micrometastases that are undetectable histologically. J Surg Res 106(1): 124-130, 2002.
78. Townson JL and Chambers AF: Dormancy of solitary metastatic cells. Cell Cycle 5(16): 1744-1750, 2006.
79. Hjortberg M and Nilsson BO: Experimental antigen modulation of blastocysts for mimicing dormant and invasive micrometastases. Ital J Anat Embryol 106(2 Suppl 2): 129-136, 2001.
80. Wikman H, Vessella R and Pantel K: Cancer micrometastasis and tumour dormancy. APMIS 116(7-8): 754-770, 2008.
81. Lesko E and Majka M: The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 13: 1271-1280, 2008. (Pubitemid 351594710)
82. You WK and McDonald DM: The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 41(12): 833-839, 2008.
83. Li HW and Shan JX: Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cells in vitro. World J Gastroenterol 11(25): 3877-3881, 2005. (Pubitemid 41025241)
84. Mohammed FF, Pennington CJ, Kassiri Z, Rubin JS, Soloway PD, Ruther U, Edwards DR and Khokha R: Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology (Baltimore, MD) 41(4): 857-867, 2005.
85. Fazekas K, Csuka O, Koves I, Raso E and Timar J: Experimental and clinicopathologic studies on the function of the HGF receptor in human colon cancer metastasis. Clin Exp Metast 18(8): 639-649, 2000.
86. Wen J, Matsumoto K, Taniura N, Tomioka D and Nakamura T: Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11(6): 419-430, 2004.
87. Naran S, Zhang X and Hughes SJ: Inhibition of HGF/MET as therapy for malignancy. Exp Opin Ther Targ 13(5): 569-581, 2009.
88. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R and Kendall R: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66(3): 1721-1729, 2006.
89. Michalopoulos GK and Khan Z: Liver regeneration, growth factors, and amphiregulin. Gastroenterology 128(2): 503-506, 2005.
90. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD and Fidler IJ: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1(1): 19-31, 1995.
91. Parker C, Roseman BJ, Bucana CD, Tsan R and Radinsky R: Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J Histochem Cytochem 46(5): 595-602, 1998. (Pubitemid 28204820)
92. Zvibel I, Brill S, Halpern Z and Papa M: Hepatocyte extracellular matrix modulates expression of growth factors and growth factor receptors in human colon cancer cells. Exp Cell Res 245(1): 123-131, 1998. (Pubitemid 28551061)
93. Ellis LM: Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin N Am 18(5): 1007-1021, viii, 2004.
94. Zhu Z: Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sinica 28(9): 1476-1493, 2007.
95. Homsi J and Daud AI: Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14(3): 285-294, 2007.
96. Byrne AM, Bouchier-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9(4): 777-794, 2005.
97. Cortes-Funes H: The role of antiangiogenesis therapy: Bevacizumab and beyond. Clin Transi Oncol 11(6): 349-355, 2009.
98. Grothey A and Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 14(3): 170-177, 2008.
99. Wipff PJ and Hinz B: Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship. Eur J Cell Biol 87(8-9): 601-615, 2008.
100. Prud'homme GJ: Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87(11): 1077-1091, 2007.
101. Hayashi H, Kohno H, Ono T, Yamanoi A, Dhar DK, Ueda S, Rahman MA, Kubota H and Nagasue N: Transforming growth factor-beta1 induced hepatocyte apoptosis - a possible mechanism for growth of colorectal liver metastasis. Acta Oncol 43(1): 91-97, 2004.
102. Picon A, Gold LI, Wang J, Cohen A and Friedman E: A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomarkers Prev 7(6): 497-504, 1998.
103. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, Matsuzawa Y and Kawata S: Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7(5): 1258-1262, 2001.
104. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML and Arteaga CL: Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117(5): 1305-1313, 2007.
105. Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11(11): S44-51, 2001.
106. Paschos KA, Canovas D and Bird NC: Enzymatic function of multiple origins regulates the progression of colorectal cancer and the development of metastases. Hippokratia 13(1): 23-31, 2009.
107. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Dano K and Nielsen BS: MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4(5): 293-302, 2006.
108. Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M and Matrisian LM: Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer 121(3): 495-500, 2007.
109. Arii S, Ishigami S, Mori A, Onodera H and Imamura M: Implication of VEGF and MMPs in hepatic metastasis of human colon cancer. Nippon Geka Gakkai Zasshi 99(7): 436-440, 1998 (in Japanese).
110. Garvin J: 'Research is in my blood': Dr. Lome Golub, developer of Periostat, receives the ADA'S Gold Medal Award for Excellence in Dental Research. J Am Dent Assoc (1939) 137(9): 1281-1282, 2006.
111. Ganea E, Trifan M, Laslo AC, Putina G and Cristescu C: Matrix metalloproteinases: useful and deleterious. Biochem Soc Transs 35(Pt 4): 689-691, 2007.